234 related articles for article (PubMed ID: 24872712)
1. Considering the role of radiation therapy for gastrointestinal stromal tumor.
Corbin KS; Kindler HL; Liauw SL
Onco Targets Ther; 2014; 7():713-8. PubMed ID: 24872712
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
4. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
5. State of the Art in the Treatment of Gastrointestinal Stromal Tumors.
Garlipp B; Bruns CJ
Gastrointest Tumors; 2014 May; 1(4):221-36. PubMed ID: 26672673
[TBL] [Abstract][Full Text] [Related]
6. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy for Gastrointestinal Stromal Tumors.
Ozkan EE
Chin Med J (Engl); 2018 Jan; 131(2):235-240. PubMed ID: 29336374
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.
Wardelmann E; Büttner R; Merkelbach-Bruse S; Schildhaus HU
Virchows Arch; 2007 Oct; 451(4):743-9. PubMed ID: 17701051
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy in the treatment of gastrointestinal stromal tumor.
Knowlton CA; Brady LW; Heintzelman RC
Rare Tumors; 2011 Oct; 3(4):e35. PubMed ID: 22355490
[TBL] [Abstract][Full Text] [Related]
10. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review.
Miettinen M; Majidi M; Lasota J
Eur J Cancer; 2002 Sep; 38 Suppl 5():S39-51. PubMed ID: 12528772
[TBL] [Abstract][Full Text] [Related]
11. The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors.
Keung EZ; Raut CP; Rutkowski P
Ann Surg Oncol; 2020 Oct; 27(10):3659-3671. PubMed ID: 32734368
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
[TBL] [Abstract][Full Text] [Related]
13. Molecular research directions in the management of gastrointestinal stromal tumors.
Tarn C; Godwin AK
Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
[TBL] [Abstract][Full Text] [Related]
14. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
15. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
17. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
[TBL] [Abstract][Full Text] [Related]
19. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
20. Management of Gastrointestinal Stromal Tumors.
Keung EZ; Raut CP
Surg Clin North Am; 2017 Apr; 97(2):437-452. PubMed ID: 28325196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
